Hematologic Malignancy
Myelodysplastic/Myeloproliferative Neoplasm
CI-CAN-00001250Explore in graph →
Hematologic115 active trials3 approved drugs6 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00001250Explore in graph →
Clinical trials
528 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (77)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02960646 | Engineered Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies | completed | Phase 1 | 11 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 16, 2023 | clinicaltrials |
| NCT00589316 | Iodine I 131 Monoclonal Antibody BC8, Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation and Donor Bone Marrow Transplant in Treating Patients With Advanced Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or High-Risk Myelodysplastic Syndrome | terminated | Phase 1 | 26 | Fred Hutchinson Cancer CenterOTHER | 1 |
| Feb 9, 2023 |
| clinicaltrials |
| NCT03746041 | A Phase I Pilot Study of Abaloparatide + Bevacizumab in Myelodysplastic Syndromes | completed | Phase 1 | 20 | University of RochesterOTHER | 1 | Jan 23, 2023 | clinicaltrials |
| NCT04022785 | PLX51107 and Azacitidine in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome | completed | Phase 1 | 43 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 31, 2022 | clinicaltrials |
| NCT05246384 | Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RP7214 in Combination With Azacitidine in Patients With Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia and Acute Myeloid Leukemia | withdrawn | Phase 1 / Phase 2 | 0 | Rhizen Pharmaceuticals SAINDUSTRY | 0 | Oct 31, 2022 | clinicaltrials |
| NCT05584761 | Unrelated Umbilical Cord Blood Stem Cell Combined With Azacitidine Based Treatment for Advanced MDS,CMML-2 and sAML | recruiting | Phase 1 / Phase 2 | 50 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Oct 18, 2022 | clinicaltrials |
| NCT02553941 | Ibrutinib and Azacitidine for Treatment of Higher Risk Myelodysplastic Syndrome | completed | Phase 1 | 21 | Brian JonasOTHER | 1 | Oct 6, 2022 | clinicaltrials |
| NCT01834248 | DEC-205/NY-ESO-1 Fusion Protein CDX-1401and Decitabine in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia | completed | Phase 1 | 9 | Roswell Park Cancer InstituteOTHER | 1 | Jul 22, 2022 | clinicaltrials |
| NCT03072043 | Phase 1b/2 Safety and Efficacy of APR-246 w/Azacitidine for tx of TP53 Mutant Myeloid Neoplasms | completed | Phase 1 / Phase 2 | 55 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Jan 24, 2022 | clinicaltrials |
| NCT03519984 | EphB4-HSA Fusion Protein and Cytarabine /or Liposomal Vincristine in Patients With Recurrent or Refractory Acute Leukemia | terminated | Phase 1 | 3 | University of Southern CaliforniaOTHER | 1 | Nov 30, 2021 | clinicaltrials |
| NCT03263637 | Study to Assess Safety, Tolerability, Pharmacokinetics and Antitumor Activity of AZD4573 in Relapsed/Refractory Haematological Malignancies | completed | Phase 1 | 44 | AstraZenecaINDUSTRY | 3 | Oct 22, 2021 | clinicaltrials |
| NCT03018223 | Calcineurin Inhibitor-Free GVHD Prevention Regimen After Related Haplo PBSCT | completed | Phase 1 | 32 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Sep 16, 2021 | clinicaltrials |
| NCT01020539 | Allogeneic Stem Cell Transplantation Followed By Targeted Immune Therapy In Average Risk Leukemia(AML/MDS/JMML) | completed | Phase 1 | 18 | Columbia UniversityOTHER | 1 | Aug 6, 2021 | clinicaltrials |
| NCT04082286 | Yttrium-90 Anti CD66 Monoclonal Antibody in Childhood Relapsed/Refractory Leukaemia | completed | Phase 1 | 9 | Great Ormond Street Hospital for Children NHS Foundation TrustOTHER | 1 | Jun 25, 2021 | clinicaltrials |
| NCT01926587 | Phase II Part 2 Expansion of Oral Rigosertib in Combination With Azacitidine | completed | Phase 1 / Phase 2 | 45 | Traws Pharma, Inc.INDUSTRY | 2 | Jun 16, 2021 | clinicaltrials |
| NCT02323178 | A Study of Eltrombopag in Patients With CMML and Thrombocytopenia | completed | Phase 1 / Phase 2 | 30 | Groupe Francophone des MyelodysplasiesOTHER | 1 | Apr 20, 2021 | clinicaltrials |
| NCT01445080 | Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia | completed | Phase 1 / Phase 2 | 70 | National Cancer Institute (NCI)NIH | 2 | Feb 2, 2021 | clinicaltrials |
| NCT01613976 | A Phase Ib Study of Panobinostat (LBH589) in Combination With 5-Azacitidine for Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML) or Acute Myeloid Leukemia (AML) Patients | completed | Phase 1 | 10 | Novartis PharmaceuticalsINDUSTRY | 1 | Dec 19, 2020 | clinicaltrials |
| NCT02029950 | Pomalidomide After Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome | completed | Phase 1 | 50 | National Cancer Institute (NCI)NIH | 1 | Oct 14, 2020 | clinicaltrials |
| NCT00809250 | Vaccination With GM-K562 Cells in Patients With Advanced Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML) After Allogeneic Hematopoetic Stem Cell Transplantation | completed | Phase 1 | 33 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 16, 2020 | clinicaltrials |
| NCT03807063 | Rivogenlecleucel Donor Lymphocyte Immunotherapy in Treating Patients With Recurrent Blood Cancers After Stem Cell Transplant | withdrawn | Phase 1 | 0 | Fred Hutchinson Cancer CenterOTHER | 1 | Aug 14, 2020 | clinicaltrials |
| NCT00946647 | A Phase Ib/IIb, Open-label, Multi-center, Study of Oral Panobinostat Administered With 5-Azacitidine (in Adult Patients With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML). | completed | Phase 1 / Phase 2 | 113 | Novartis PharmaceuticalsINDUSTRY | 14 | Aug 4, 2020 | clinicaltrials |
| NCT00054236 | Combination Chemotherapy Followed By Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer or Severe Aplastic Anemia | completed | Phase 1 | 55 | Case Comprehensive Cancer CenterOTHER | 1 | Jul 27, 2020 | clinicaltrials |
| NCT02546284 | Study of Lenzilumab in Previously Treated Patients With Chronic Myelomonocytic Leukemia (CMML) | completed | Phase 1 | 15 | Humanigen, Inc.INDUSTRY | 1 | Feb 28, 2020 | clinicaltrials |
| NCT00006251 | Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine, Mycophenolate Mofetil, Donor Lymphocyte Infusion in Treating Patients With Hematopoietic Cancer | completed | Phase 1 / Phase 2 | 21 | Fred Hutchinson Cancer CenterOTHER | 2 | Jan 21, 2020 | clinicaltrials |
| NCT00078858 | Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant | completed | Phase 1 / Phase 2 | 37 | Fred Hutchinson Cancer CenterOTHER | 3 | Jan 18, 2020 | clinicaltrials |
| NCT00027820 | Total-Body Irradiation and Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer | completed | Phase 1 / Phase 2 | 106 | Fred Hutchinson Cancer CenterOTHER | 3 | Dec 20, 2019 | clinicaltrials |
| NCT00036790 | Motexafin Gadolinium and Doxorubicin in Treating Patients With Advanced Cancer | completed | Phase 1 | — | University of Wisconsin, MadisonOTHER | 1 | Dec 17, 2019 | clinicaltrials |
| NCT01629082 | Clofarabine Followed By Lenalidomide for High-Risk Myelodysplastic Syndromes and Acute Myeloid Leukemia | completed | Phase 1 | 4 | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | Dec 17, 2019 | clinicaltrials |
| NCT01300572 | Yttrium-90 Anti-CD45 Monoclonal Antibody BC8 Followed by Donor Stem Cell Transplant in Treating Patients With High-Risk AML, ALL, or MDS | completed | Phase 1 | 16 | Fred Hutchinson Cancer CenterOTHER | 1 | Dec 10, 2019 | clinicaltrials |
| NCT00085449 | Alemtuzumab Plus Fludarabine and Melphalan With or Without Cyclosporine, Mycophenolate Mofetil, and Low-Dose Total-Body Irradiation Therapy Followed by Donor Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Alliance for Clinical Trials in OncologyOTHER | 1 | Nov 27, 2019 | clinicaltrials |
| NCT02129101 | Azacitidine and Sonidegib or Decitabine in Treating Patients With Myeloid Malignancies | completed | Phase 1 | 63 | Mayo ClinicOTHER | 1 | Oct 30, 2019 | clinicaltrials |
| NCT00101179 | MS-275 and Azacitidine in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia | completed | Phase 1 | 63 | National Cancer Institute (NCI)NIH | 1 | Oct 18, 2019 | clinicaltrials |
| NCT02749708 | Study of IRX5183 in Relapsed and Refractory Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome | terminated | Phase 1 | 13 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Apr 22, 2019 | clinicaltrials |
| NCT02418000 | A Study of E6201 for the Treatment of Advanced Hematologic Malignancies With FLT3 and/or Ras Mutations | terminated | Phase 1 / Phase 2 | 27 | Spirita Oncology, LLCINDUSTRY | 1 | Mar 20, 2019 | clinicaltrials |
| NCT01165996 | Differentiation Therapy With Decitabine in Treating Patients With Myelodysplastic Syndrome | completed | Phase 1 / Phase 2 | 25 | Case Comprehensive Cancer CenterOTHER | 1 | Mar 4, 2019 | clinicaltrials |
| NCT00002746 | Interleukin-2 in Treating Patients With Myelodysplastic Syndrome | completed | Phase 1 | 24 | University of WashingtonOTHER | 1 | Feb 27, 2019 | clinicaltrials |
| NCT00039091 | Monoclonal Antibody Therapy in Treating Patients With Ovarian Epithelial Cancer, Melanoma, Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Non-Small Cell Lung Cancer | terminated | Phase 1 | 26 | National Cancer Institute (NCI)NIH | 1 | Sep 5, 2018 | clinicaltrials |
| NCT01484015 | Prolonged or Standard Infusion of Cefepime Hydrochloride in Treating Patients With Febrile Neutropenia | completed | Phase 1 | 70 | Wake Forest University Health SciencesOTHER | 1 | Jul 18, 2018 | clinicaltrials |
| NCT02210858 | Tipifarnib in Treating Patients With Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or Undifferentiated Myeloproliferative Disorders | completed | Phase 1 / Phase 2 | 31 | National Cancer Institute (NCI)NIH | 1 | Jun 4, 2018 | clinicaltrials |
| NCT01757639 | Ipilimumab in Treating Patients With Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia | completed | Phase 1 | 42 | National Cancer Institute (NCI)NIH | 1 | Mar 21, 2018 | clinicaltrials |
| NCT00852709 | Phase I Dose-Escalation Trial of Clofarabine Followed by Escalating Doses of Fractionated Cyclophosphamide in Children With Relapsed or Refractory Acute Leukemias(POE07-01) | terminated | Phase 1 | 35 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 2 | Feb 15, 2018 | clinicaltrials |
| NCT00908167 | Sorafenib in Combination With Cytarabine and Clofarabine in Patients With Refractory or Relapsed Hematologic Malignancies | completed | Phase 1 | 44 | St. Jude Children's Research HospitalOTHER | 1 | Jan 12, 2018 | clinicaltrials |
| NCT00006239 | Phenylbutyrate and Tretinoin in Treating Patients With Hematologic Cancer | completed | Phase 1 | — | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Sep 29, 2017 | clinicaltrials |
| NCT00245037 | Busulfan, Fludarabine, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic Cancer(Bu Flu TBI) | completed | Phase 1 / Phase 2 | 147 | OHSU Knight Cancer InstituteOTHER | 1 | Sep 27, 2017 | clinicaltrials |
| NCT00988715 | Donor Peripheral Blood Stem Cell Transplant and Pretargeted Radioimmunotherapy in Treating Patients With High-Risk Advanced Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome | completed | Phase 1 | 17 | Fred Hutchinson Cancer CenterOTHER | 1 | Aug 30, 2017 | clinicaltrials |
| NCT00624936 | Azacytidine and Bortezomib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes | completed | Phase 1 | 23 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Aug 22, 2017 | clinicaltrials |
| NCT01169012 | PK Study of Oral and IV Clofarabine in High Risk Myelodysplasia+Acute Leukemias | completed | Phase 1 | 13 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Aug 22, 2017 | clinicaltrials |
Data updated 22 days agoSource updated Feb 16, 2023source: clinicaltrials